EyePoint

EYPT · NASDAQ

$0.4052−$0.0348 (−7.91%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $0.44

About EYPT

EyePoint Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. The company is headquartered in Watertown, Massachusetts and currently employs 214 full-time employees. The company went IPO on 2005-01-27. The firm is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.

Employees: 214
Headquarters: Watertown, Massachusetts
Listed: Jan 27, 2005
Sector: Health Care
Industry: Pharmaceuticals
Website: eyepoint.bio

Leadership

EyePoint executives
Name	Title	Since	Age
Goeran Ando	—	—	75
Jay Duker	—	2016	66
Nancy Lurker	—	2016	67
George Elston	—	—	60
Ramiro Ribeiro	—	—	42
Wendy Dicicco	—	—	57
Stuart Duty	—	—	60
Fred Hassan	—	—	79
John Landis	—	—	72
Reginald Sanders	—	—	66
Karen Zaderej	—	—	63
Stern ..	—	2022	—

Revenue by product and region

Fiscal year ended Dec 31, 2025: $31.37M total revenue

By product

Product [Member]$900.00K286.9%
Royalty Income [Member]$400.00K127.5%
License and Collaboration Agreements [Member]$100.00K31.9%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

EyePoint suppliers and customers
Company	Relationship	Country	Correlation
McKesson MCK	Customer	US	0.31
AmerisourceBergen ABC	Customer	US	0.21
Harrow Health HROW	Supplier and customer	US	-0.04
Betta Pharmaceuticals A	Supplier and customer	CN	-0.25
Ocumension	Supplier and customer	CN	-0.35
Oncosil Medical OSL.AX	Supplier and customer	AU	-0.40
Alimera Sciences ALIM	Supplier and customer	US	-0.45
Ramscor, Inc.	Supplier and customer	US	—
Tyrogenex, Inc.	Supplier and customer	US	—

Similar companies

Companies in the same industry as EyePoint

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.